Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain r…
Drug Manufacturers - Specialty & Generic
GB, Weybridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | inf | 0.00 | 1.04 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -94.41 | 1.54 | 27.58 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 15.12 | 3.64 | 3.16 | |
| Cash | 14.27 | 0.23 | 0.20 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | |
| Revenue | 20.59 | 0.63 | 0.53 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 17.60 | 0.63 | 0.54 | |
| Operating Margin | 131.48 | 0.23 | 0.10 | |
| ROA | inf | 0.00 | < 0.005 | |
| ROE | 13896.33 | 0.03 | < 0.005 | |
| ROIC | 6889.46 | 0.03 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of HLN is permitted for members.
5
Growth
The "Growth Entry" for the Focus of HLN is permitted for members.
6
Leverage & Liquidity